,,ii #aagth ,,congress #b;d ,session ,s4 #eabc ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,november #ag1 #bjbb,mr4 ,booker 7for himself and ,mr4 ,paul7 introduced the following bill2 which was read twice and referred to the ,committee on the ,judiciary ,a ,,bill ,to amend the ,controlled ,substances ,act to modify the registration requirements relating to research1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,breakthrough ,therapies ,act4 #b4 ,registration requirements related to research 7a7 ,alternative registration process for schedule ,i research ,section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7 is amended by adding at the end the following new subsection3 7l7 ,special provisions for those conducting certain research with schedule i controlled substances 7#a7 ,in general ,notwithstanding subsection 7f71 a practitioner may conduct research that is described by paragraph 7#b7 and that is with #a or more schedule ,i substances if one of the following conditions is satisfied3 7,a7 ,researcher with a current schedule ,i or ,,ii research registration ,if the practitioner is registered to conduct research with a controlled substance in schedule ,i or ,,ii1 the practitioner may conduct research under this paragraph #cj days after the practitioner has sent a notice to the ,attorney ,general containing the following information1 with respect to each substance with which the research will be conducted3 7i7 ,the chemical name of the substance4 7ii7 ,the quantity of the substance to be used in such research4 7iii7 ,demonstration that the research is in the category described by paragraph 7#b71 which demonstration can be satisfied-- 7,i7 in the case of a grant1 contract1 cooperative agreement1 or other transaction1 or intramural research project1 by identifying the sponsoring agency and supplying information related to the grant1 contract1 cooperative agreement1 other transaction1 or project2 or 7,,ii7 in the case of an application under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 by supplying the application number and the sponsor of record on such application4 7iv7 ,demonstration that the researcher is authorized to conduct research with respect to the substance under the laws of the ,state in which the research will take place4 7,b7 ,researcher without a current schedule ,i or ,,ii 7i7 ,research registration ,if the practitioner is not currently registered to conduct research with a controlled substance in schedule ,i or ,,ii1 the practitioner may send a notice to the ,attorney ,general containing the information listed in subparagraph 7,a71 with respect to each substance with which the research will be conducted1 and the ,attorney ,general will treat such notice as a sufficient application for a research registration4 ,not later than #de days of receiving such a notice that contains all information required by subparagraph 7,a71 the ,attorney ,general shall register the applicant1 or serve an order to show cause upon the applicant in accordance with section #hbd7;c7 of this title4 7,c7 ,verification of information ,on request from the ,attorney ,general1 the ,secretary of ,health and ,human ,services or the ,secretary of ,veterans ,affairs1 as appropriate1 shall verify information submitted by an applicant under subparagraph 7,a77iii74 7#b7 ,research subject to expedited procedure ,research is described by this paragraph if-- 7,a7 the research is the subject of an application under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act for the investigation of a drug which is in effect in accordance with section #cab4dj of title #ba1 ,code of ,federal ,regulations2 or 7,b7 the research is conducted by the ,department of ,health and ,human ,services or the ,department of ,veterans ,affairs or is funded partly or entirely by a grant1 contract1 cooperative agreement1 or other transaction from the ,department of ,health and ,human ,services1 ,department of ,veterans ,affairs1 or a ,state health department4 7#c7 ,electronic submissions ,the ,attorney ,general shall provide a means to permit practitioners to submit notifications under paragraph 7#a7 electronically4 7#d7 ,limitation on amounts ,a practitioner conducting research with a schedule ,i substance pursuant to this subsection shall only be permitted to possess the amounts of schedule ,i substance identified in-- 7,a7 the notification to the ,attorney ,general under paragraph 7#a72 or 7,b7 a supplemental notification that the practitioner may send if the practitioner needs additional amounts for the research1 which supplemental notification shall include the registrant's name1 the additional quantity needed of the substance1 and an attestation that the research to be conducted with the substance is consistent with the scope of the research that was the subject of the notification under paragraph 7#a74 7#e7 ,importation and exportation requirements not affected ,nothing in this section alters the requirements of part ,a of title ,,iii1 regarding the importation and exportation of controlled substances4 4 7b7 ,separate registrations not required for additional researcher in same institution ,section #cjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbb7 is amended in subsection 7c71 by adding the following paragraph3 7#d7 ,an agent or employee of a research institution that is conducting research with a controlled substance if-- 7,a7 such agent or employee is acting within the scope of his or her professional practice2 7,b7 another agent or employee of such institution is registered to conduct research with a controlled substance in the same schedule2 7,c7 the researcher who is so registered-- 7i7 informs the ,attorney ,general of the name1 position title1 and employing institution of the agent or employee who is not separately registered2 7ii7 authorizes such agent or employee to perform research under the registered researcher's registration2 and 7iii7 affirms that all acts taken by such agent or employee involving controlled substances shall be attributable to the registered researcher1 as if the researcher had directly committed such acts1 for purposes of any proceeding under section #cjd7;a7 7#ba ,u4,s4,c4 #hbd7;a77 to suspend or revoke the registration of the registered researcher2 and 7,d7 the ,attorney ,general does not1 within #cj days of receiving the information1 authorization1 and affirmation described in subparagraph 7,c71 refuse1 for a reason listed in section #cjd7;a7 7#ba ,u4,s4,c4 #hbd7;a771 to allow such agent or employee to possess such substance without a separate registration4 4 7c7 ,single registration for related research sites ,such section #cjb is further amended in subsection 7e7 by adding at the end the following new paragraph3 7#c7 7,a7 ,notwithstanding paragraph 7#a71 a person registered to conduct research with a controlled substance under section #cjc7;f7 may conduct such research under a single registration if-- 7i7 such research occurs exclusively on sites all of which are within the same city or county and are under the control of the same institution1 organization1 or agency2 and 7ii7 the researcher notifies the ,attorney ,general of all sites where the research will be conducted or where the controlled substance will be stored or administered prior to commencing such research4 7,b7 ,a site described by subparagraph 7,a7 shall be included in such registration only if the researcher has notified the ,attorney ,general of such site-- 7i7 in the application for such registration2 or 7ii7 before the research is conducted1 or before the controlled substance is stored or administered1 at such site4 7,c7 ,the ,attorney ,general may1 in consultation with the ,secretary of ,health and ,human ,services1 issue regulations addressing-- 7i7 the manner in which controlled substances may be delivered to the research sites described in subparagraph 7,a72 7ii7 the storage and security of controlled substances at such research sites2 7iii7 the maintenance of records for such research sites2 and 7iv7 any other matters necessary to ensure effective controls against diversion at such research sites4 4 7d7 ,new inspection not required in certain situations ,such section #cjb is further amended in subsection 7f7-- 7#a7 by striking 7f7 ,the and inserting 7f77#a7 ,the2 and 7#b7 by adding a new paragraph1 as follows3 7#b7 7,a7 ,if a person is registered to conduct research with a controlled substance and applies for a registration1 or for a modification of a registration1 to conduct research with a second controlled substance that is in the same schedule as the first controlled substance1 or is in a schedule with a higher numerical designation than the schedule of the first controlled substance1 a new inspection by the ,attorney ,general of the registered location is not required4 7,b7 ,nothing in this paragraph shall prohibit the ,attorney ,general from conducting any inspection if the ,attorney ,general deems it necessary to ensure that the registrant maintains effective controls against diversion4 4 7e7 ,continuation of research on substances newly added to schedule i ,such section #cjb is further amended by adding at the end the following new subsection3 7h7 ,continuation of research on substances newly added to schedule ,i ,if a person is conducting research on a substance at the time the substance is added to schedule ,i1 and such person is already registered to conduct research with a controlled substance in schedule ,i1 then-- 7#a7 the person shall1 not later than #ij days of the scheduling of the newly scheduled substance1 submit a completed application for registration or modification of existing registration1 to conduct research on such substance1 in accordance with the regulations issued by the ,attorney ,general2 7#b7 the person may1 notwithstanding subsections 7a7 and 7b71 continue to conduct the research on such substance until the person withdraws such application or until the ,attorney ,general serves on the person an order to show cause proposing the denial of the application pursuant to section #cjd7;c72 7#c7 if the ,attorney ,general serves such an order to show cause and the person requests a hearing1 such hearing shall be held on an expedited basis and not later than #de days after the request is made1 except that the hearing may be held at a later time if so requested by the person2 and 7#d7 if the person sends a copy of the application referred to in that paragraph to a manufacturer or distributor of such substance1 receipt of such copy by such manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive such substance4 4 7f7 ,treatment of certain manufacturing activities as coincident to research ,such section #cjb 7#ba ,u4,s4,c4 #hbb7 is further amended by adding at the end the following new subsection3 7j7 ,treatment of certain manufacturing activities as coincident to research 7#a7 ,in general ,except as specified in paragraph 7#c71 a person who is registered to perform research on a controlled substance may perform manufacturing activities with small quantities of that substance1 including activities listed in paragraph 7#b71 without being required to obtain a manufacturing registration1 if such activities are performed for the purpose of the research and if the activities and the quantities of the substance involved in those activities are stated in-- 7,a7 a notification submitted to the ,attorney ,general under section #cjc7l72 7,b7 a protocol filed with an application for registration approval1 under section #cjc7;f72 or 7,c7 a notification to the ,attorney ,general that includes the registrant's name and an attestation that the research to be conducted with the small quantities of manufactured substance is consistent with the scope of the research that is the basis for the registration4 7#b7 ,activities included ,activities permitted under paragraph 7#a7 include-- 7,a7 processing the substance to create extracts1 tinctures1 oils1 solutions1 derivatives1 or other forms of the substance consistent the information provided as part of a notification submitted to the ,attorney ,general under section #cjc7l7 7#ba ,u4,s4,c4 #hbc7l77 or a research protocol filed with the application for registration approval2 and 7,b7 dosage form development studies performed for the purpose of satisfying ,,fda regulatory requirements for submitting an investigational new drug application4 7#c7 ,exception regarding marihuana ,the authority under paragraph 7#a7 to manufacture substances does not include authority to grow marihuana4 4 7g7 ,transparency regarding special procedures ,section #cjc of such ,act 7#ba ,u4,s4,c4 #hbc7 is further amended by adding at the end the following new subsection3 7m7 ,transparency regarding special procedures 7#a7 ,in general ,if the ,attorney ,general determines1 with respect to a controlled substance1 that an application by a practitioner to conduct research with such substance should be considered under a process1 or subject to criteria1 different from the process or criteria applicable to applications to conduct research with other controlled substances in the same schedule1 the ,attorney ,general shall make public1 including by posting on the website of the ,drug ,enforcement ,administration-- 7,a7 the identities of all substances for which such determinations have been made2 7,b7 the process and criteria that shall be applied to applications to conduct research with such substances2 and 7,c7 how such process and criteria differ from those applicable to applications to conduct research with other controlled substances in the same schedule4 7#b7 ,timing of posting ,the ,attorney ,general shall make such information public upon making such determination1 regardless of whether a practitioner has submitted such an application at that time4 4 #c4 ,currently accepted medical use with severe restrictions 7a7 ,definitions ,section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb7 is amended by inserting after paragraph 7#g7 the following3 7#g7 7,a7 ,subject to subparagraph 7,b71 the term currently accepted medical use with severe restrictions1 with respect to a drug or other substance1 includes a drug or other substance that is an active moiety or active ingredient 7whether in natural or synthetic form7 of an investigational new drug for which a waiver is in effect under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;i77 or section #cea7;a77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;a77#c77 and that the ,secretary-- 7i7 designates as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a772 or 7ii7 authorizes for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb71 either alone or as part of a therapeutic protocol1 to treat patients with serious or life-threatening diseases for which no comparable or satisfactory therapies are available4 7,b7 ,a drug or other substance shall not meet the criteria under subparagraph 7,a7 for having a currently accepted medical use with severe restrictions if-- 7i7 in the case of a drug or other substance described in subparagraph 7,a77ii7-- 7,i7 the ,secretary places the expanded access or protocol for such drug on clinical hold as described in section #cab4db of title #ba1 ,code of ,federal ,regulations 7or any successor regulations72 7,,ii7 there is no other investigational new drug containing the drug or other substance for which expanded access has been authorized under section #efa7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb7a772 and 7,,iii7 the drug or other substance does not meet the requirements of subparagraph 7,a77i72 or 7ii7 the drug or other substance is an active moiety or active ingredient 7whether natural or synthetic7 of an application approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb74 4 7b7 ,authority and criteria for classification of substances ,section #bja7;j7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa7;j77 is amended-- 7#a7 in paragraph 7#a71 by inserting a drug designated as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a771 or a drug authorized for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb7 after subsection 7f712 and 7#b7 in paragraph 7#b7-- 7,a7 in subparagraph 7,a71 by striking 2 or and inserting a semicolon2 7,b7 in subparagraph 7,b71 by striking the period at the end and inserting a semicolon2 and 7,c7 by adding at the end the following3 7,c7 the date on which the ,attorney ,general receives notification from the ,secretary of ,health and ,human ,services that the ,secretary has designated a drug as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a77 or authorized a drug for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb72 or 7,d7 the date on which the ,attorney ,general receives any written notification demonstrating that the ,secretary1 before the date of enactment of this subparagraph1 designated a drug as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a77 or authorized a drug for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb74 4